Onconic Therapeutics Inc. (KOSDAQ:476060)

South Korea flag South Korea · Delayed Price · Currency is KRW
11,500
-1,740 (-13.14%)
Jul 21, 2026, 3:30 PM KST
Market Cap522.19B +70.1%
Revenue (ttm)67.20B +196.2%
Net Income20.33B
EPS441.04
Shares Out 45.41M
PE Ratio26.08
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume696,856
Open12,550
Previous Close13,240
Day's Range11,260 - 12,700
52-Week Range5,663 - 28,900
Betan/a
Analystsn/a
Price Targetn/a
Earnings DateMar 20, 2026

About Onconic Therapeutics

Onconic Therapeutics Inc. engages in the research and development of anti-cancer therapy in South Korea. It develops Zastaprazan (OCN-101), a potassium-competitive acid blocker, which is in phase 3 for the treatment of gastric acid related disease; and OCN-201 (JPI-547), an anticancer drug; JP-1366, a treatment for peptic ulcer; and drugs for DDR and immuno-oncology fields. JP-1366, a poly ADP-ribose polymerase inhibitor, which is in phase 1 for the treatment of pancreatic cancer. The company was founded in 2020 and is based in Seoul, South Kor... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2020
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 476060
Full Company Profile

Financial Performance

Financial Statements